Aspatrend

acute and chronic liver diseases accompanied by hyperammonemia,

hepatic encephalopathy, including as part of the complex therapy of impaired consciousness (precoma and coma),

as a corrective supplement to preparations for parenteral nutrition in patients with protein deficiency.

acute and chronic liver diseases accompanied by hyperammonemia,

hepatic encephalopathy (latent and severe),

steatoses and steatohepatitis (of various origins).

Hyperammonemia, hepatoencephalitis, chronic alcohol intoxication, hepatitis, cirrhosis of the liver, severe liver failure, hepatic colic, coma, acute hepatitis, portocaval encephalopathies.

V/v, drip. The contents of the ampoules are mixed with 500 ml of infusion solution (0.9% sodium chloride solution, 5% dextrose (glucose) solution or Ringer's solution).

Adults. The average therapeutic dose of ornithine is 20 g/day.

In hepatic encephalopathy (depending on the severity of the condition), up to 40 g/day of ornithine is administered intravenously.

It is recommended to dissolve no more than 30 g of ornithine in 500 ml of infusion solution. The maximum infusion rate is 5 g / h of ornithine.

The duration of therapy with the drug is determined in each case individually, based on the pathology and severity of the patient's condition. In severe liver function disorders, strict monitoring of the patient's condition and correction of the rate of administration of the drug is necessary to prevent the development of nausea and vomiting.

Children. There is no data on the use of the drug in pediatric practice.

Inside, after eating, 1-2 packs. granules, previously dissolved in 200 ml of liquid, 3 times a day. The course of administration depends on the severity of the disease.

In/in (jet, drip), in / m. For intravenous infusion or perfusion, 5 g of powder dissolved in 10 ml of distilled water is injected into an infusion solution (saline, blood substitutes, glucose, etc.) and poured drip (40 drops/min or slower — from 2 to 12 hours) for 5-10 vials per day.

hypersensitivity to the components of the drug,

severe renal insufficiency (serum creatinine >3 mg/1 dl),

breastfeeding period,

children under 18 years of age.

hypersensitivity to the components of the drug,

severe renal insufficiency with a creatinine reading of more than 3 mg/100 ml,

lactation period,

children's age (due to insufficient data).

With caution: pregnancy.

Severe renal insufficiency (creatinine level greater than 3 mg/100 ml).

Very rarely (less than 0.01%) - nausea, vomiting, allergic reactions.

From the gastrointestinal tract: infrequently-nausea, vomiting, abdominal pain, flatulence, diarrhea.

Musculoskeletal and connective tissue disorders: very rarely-pain in the extremities.

The dye "Sunny Sunset" yellow can cause allergic reactions.

In some cases, nausea, vomiting.

Symptoms: increased severity of dose-dependent side effects.

Treatment: the drug should be discontinued and symptomatic treatment should be carried out.

Symptoms: increased severity of side effects.

Treatment: gastric lavage, administration of activated charcoal, symptomatic therapy.

Reduces the increased concentration of ammonia in the body, in particular in liver diseases. The effect of the drug is associated with its participation in the ornithine cycle of Krebs urea formation (formation of urea from ammonia). Ornithine acts as a catalyst for the enzymes carbamoyl phosphate synthetase and ornithine carbamoyl transferase, and is also the basis for the synthesis of urea. In addition, the drug activates the ornithine cycle of urea formation, which also helps to reduce the level of ammonia. Promotes the production of insulin and somatotropic hormone. Improves protein metabolism in diseases that require parenteral nutrition

It has a detoxifying effect, reducing the increased level of ammonia in the body, in particular in liver diseases. The effect of the drug is associated with its participation in the ornithine cycle of Krebs urea formation (activates the cycle, restoring the activity of liver cell enzymes: ornithine-carbamoyl transferase and carbamoyl-phosphate synthetase). Promotes the production of insulin and somatotropic hormone.

Improves protein metabolism in diseases that require parenteral nutrition.

It helps to reduce asthenic, dyspeptic and pain syndromes, as well as normalize increased body weight (with steatosis and steatohepatitis).

In vivo it forms 2 active metabolites: aspartate and ornithine, which have a short T_1/2 0.3-0.4 h, excreted by the kidneys through a cycle of urea formation. A small part of aspartate is excreted unchanged by the kidneys.

L-ornithine-L-aspartate quickly dissociates into ornithine and aspartate and begins to act within 15-25 minutes, having a short T_1/2. It is excreted in the urine through a cycle of urea formation.

• Hypo-azotemic agent [Detoxifying agents, including antidotes]
• Hypo-azotemic agent [Hepatoprotectors]

• Drugs for the treatment of liver diseases [Detoxifying agents, including antidotes]
• Drugs for the treatment of liver diseases [Hepatoprotectors]

• Detoxifying agents, including antidotes
• Hepatoprotectors

Not detected.

Aspatrend^® it should not be mixed with other medicines. For dilution, use only the solutions specified in the description.

Not described.

Incompatible with penicillin, vitamin K, rifampicin, meprobamate, diazepam, phenobarbital, ethionamide.